Eisai-Biogen Alzheimer's Drug Shows Amyloid Reduction, Disease-Modifying Effect

Eisai and Biogen today announced positive updates on the Phase IIB 201 and open-label extension (OLE) studies they are conducting on the use of lecanemab to treat early Alzheimer's Disease (AD).